Does Losartan Decrease Potassium?
No, losartan does NOT decrease potassium—it INCREASES serum potassium levels and can cause hyperkalemia. This is a fundamental property of all renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin receptor blockers like losartan 1.
Mechanism of Potassium Elevation
Losartan blocks the angiotensin II type 1 (AT1) receptor, which normally stimulates aldosterone secretion from the adrenal cortex 1. By blocking this receptor, losartan reduces aldosterone levels, leading to decreased potassium excretion by the kidneys and subsequent elevation of serum potassium 2.
Clinical Evidence
FDA Drug Label Warnings
The FDA explicitly warns that losartan can cause hyperkalemia and requires periodic monitoring of serum potassium 1. The drug label specifically states that coadministration with other drugs that raise serum potassium may result in hyperkalemia 1.
Research Data Supporting Potassium Elevation
High-dose vs. low-dose losartan (HEAAL trial, 2023): High-dose losartan (150 mg/day) increased the risk of hyperkalemia by 21% compared to low-dose (50 mg/day) [HR 1.21,95% CI 1.05-1.39] 3. Notably, this study found that hypokalemia (≤3.5 mmol/L) was actually associated with worse outcomes than hyperkalemia, and high-dose losartan reduced the risk of hypokalemia 3.
RENAAL trial analysis (2011): In patients with type 2 diabetes and nephropathy, 38.4% of losartan-treated patients developed serum potassium ≥5.0 mmol/L at 6 months, compared to only 22.8% in the placebo group (p<0.001) 4. Losartan was an independent predictor for elevated potassium (OR 2.8,95% CI 2.0-3.9) 4.
Comparative study with enalapril (2001): In renal transplant recipients, losartan caused less potassium elevation than the ACE inhibitor enalapril (4.5 vs 4.8 mmol/L), but still increased potassium above baseline 5. This is because losartan doesn't suppress aldosterone as completely as ACE inhibitors 5.
Clinical Management Guidelines
Monitoring Requirements
Monitor serum potassium within 1 week of starting losartan or following any dose escalation 6. The European Society of Cardiology provides specific thresholds:
- K+ 4.5-5.0 mEq/L: Continue losartan with close monitoring; initiate potassium-lowering therapy if K+ rises >5.0 6
- K+ >5.0 to 6.5 mEq/L: Continue maximum-tolerated losartan dose but initiate potassium-lowering therapy 6
- K+ >6.5 mEq/L: Discontinue or reduce losartan; start potassium-lowering therapy 6
Risk Factors for Hyperkalemia on Losartan
Patients at highest risk include those with 2, 1:
- Advanced chronic kidney disease (up to 73% develop hyperkalemia)
- Diabetes mellitus
- Concomitant use of potassium-sparing diuretics, NSAIDs, or other RAAS inhibitors
- Volume depletion
- Advanced age
Critical Pitfall to Avoid
Do NOT confuse losartan's effect with thiazide diuretics. When losartan is combined with hydrochlorothiazide (HCTZ), the thiazide component causes potassium loss, which can mask or counteract losartan's potassium-elevating effect 7. In one study, the losartan/HCTZ combination actually decreased serum potassium, but this was due to the HCTZ, not the losartan 7.
Dual RAAS Blockade Warning
Never combine losartan with ACE inhibitors or aliskiren in patients with diabetes 1. The VA NEPHRON-D trial demonstrated that combining losartan with lisinopril significantly increased hyperkalemia and acute kidney injury without additional benefit 1.